Idea principal
In 405 Chinese adults with overweight or obesity and early type 2 diabetes, 16 weeks of a 5:2 meal-replacement diet cut HbA1c by 1.9%, more than metformin (1.6%) or empagliflozin (1.5%). The trial was open-label, lasted only 16 weeks with an 8-week follow-up, and 332 participants completed treatment.
Study design
Ensayo aleatorizado
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Intermittent fasting with meal replacements could offer extra benefits to people with type 2 diabetes, but it has rarely been compared with standard diabetes drugs. The EARLY trial tested whether a 5:2 meal-replacement diet (2 non-consecutive fasting days and 5 days of habitual intake per week) improves blood sugar control in early diabetes compared with metformin and empagliflozin.
Población y método
Randomized, open-label, active parallel-controlled trial at 9 centers across China, conducted between November 13, 2020, and December 29, 2022. Of 509 patients screened, 405 with newly diagnosed overweight or obese type 2 diabetes were randomly assigned 1:1:1 to metformin, empagliflozin or the 5:2 meal-replacement diet (5:2 MR) and analyzed by intention to treat. Treatment lasted 16 weeks with an 8-week follow-up. The primary end point was the change in hemoglobin A1c (HbA1c) from baseline to 16 weeks; secondary end points included body weight, anthropometric measures and biochemical parameters. Registered as ChiCTR2000040656.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Participants had a mean age of 45.5 years (SD 11.0), mean BMI 29.5 (SD 4.1) and mean HbA1c 7.9% (SD 0.6%); 265 (65.4%) were men and 332 of 405 completed the 16-week treatment.
- 2HbA1c fell most in the 5:2 MR group (least-squares mean, LSM, -1.9%, SE 0.2%), compared with metformin (LSM -1.6%, SE 0.2%) and empagliflozin (LSM -1.5%, SE 0.2%).
- 3The adjusted LSM difference was -0.3% (95% CI -0.4% to -0.1%) versus metformin and -0.4% (95% CI -0.6% to -0.2%) versus empagliflozin.
- 4Weight loss at week 16 was greater with 5:2 MR (LSM -9.7 kg, SE 2.2 kg) than with metformin (LSM -5.5 kg, SE 2.3 kg) or empagliflozin (LSM -5.8 kg, SE 2.3 kg).
Límites e incertidumbre
- 1The trial was open-label, so participants and clinicians knew who was on the diet, which can inflate weight and self-managed behavior effects.
- 2Treatment lasted only 16 weeks, with 8 weeks of follow-up, so the abstract cannot show whether the HbA1c and weight advantage lasts, or whether people stay on the diet.
- 3Only Chinese adults with early, overweight or obese type 2 diabetes were included, and only 332 of 405 completed treatment, so results may not apply to longer-standing diabetes or other populations.
- 4This reading is based on the abstract only.
Relevancia práctica
For some people with newly diagnosed type 2 diabetes and excess weight, a supervised short-term fasting plan using meal replacements lowered blood sugar and weight at least as much as two common drugs. This does not mean anyone should stop medication or begin fasting on their own; fasting with diabetes can be risky, so decisions belong with your clinician.
Tus datos
If your clinician supports a plan like this, a weight scale trend, food logs and, if prescribed, a glucose meter or CGM can show how you respond. Measure at the same time of day under the same conditions, and rely on HbA1c from the lab for the main picture.
Cómo interpretar la evidencia
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Importance
An intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake per week and meal replacement diet (5:2 MR) could provide additional benefits to patients with type 2 diabetes.
Objective
To evaluate the effect of the 5:2 MR on glycemic control among patients with early type 2 diabetes compared with metformin and empagliflozin.
Design, setting, and participants
The EARLY (Exploration of Treatment of Newly Diagnosed Overweight/Obese Type 2 Diabetes Mellitus) study is a randomized, open-label, active parallel-controlled clinical trial conducted between November 13, 2020, and December 29, 2022, in 9 centers across China. A total of 509 eligible patients underwent screening, out of which 405 were randomly assigned to 3 groups and included in the intention-to-treat analysis.
Interventions
Patients were randomly allocated in a 1:1:1 ratio to receive either metformin, empagliflozin, or 5:2 MR. The treatment was 16 weeks, with an 8-week follow-up.
Main outcomes and measures
The primary end point was the change in hemoglobin A1c (HbA1c) level from baseline to 16 weeks. Secondary end points included changes in body weight, anthropometric measurements, and biochemical parameters.
Results
Of the 405 randomized participants (265 men [65.4%]; mean [SD] age, 45.5 [11.0] years; mean [SD] body mass index, 29.5 [4.1]; and mean [SD] HbA1c level, 7.9% [0.6%]), 332 completed the 16-week treatment. From baseline to week 16, participants in the 5:2 MR group showed the greatest reduction in HbA1c (least-squares mean [LSM], -1.9% [SE, 0.2%]), significantly greater than patients receiving metformin (LSM, -1.6% [SE, 0.2%]; adjusted LSM difference, -0.3% [95% CI, -0.4% to -0.1%]) and empagliflozin (LSM, -1.5% [SE, 0.2%]; adjusted LSM difference, -0.4% [95% CI, -0.6% to -0.2%]). At week 16, the mean weight loss in the 5:2 MR group (LSM, -9.7 kg [SE, 2.2 kg]) was greater than that in the metformin group (LSM, -5.5 kg [SE, 2.3 kg]) and empagliflozin group (LSM, -5.8 kg [SE, 2.3 kg]).
Conclusions and relevance
This randomized clinical trial of Chinese adults with overweight or obesity and with early type 2 diabetes found that 5:2 MR could improve glycemic outcomes and weight loss in the short term compared with metformin or empagliflozin, making it a promising initial intervention and early management for type 2 diabetes.
Trial registration
Chinese Clinical Trial Registry Identifier: ChiCTR2000040656.
Fuentes y atribución
A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes: The EARLY Randomized Clinical Trial.
Guo L, Xi Y, Jin W, Yuan H, Qin G, Chen S, Zhang L, Liu Y, Cheng X, Liu W, Yu D.
JAMA network open · 2024-06-03
DOI: 10.1001/jamanetworkopen.2024.16786 ↗PubMed · 38904963 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

